Companies · Pharmaceuticals

Macrotope, Inc.

PRINCETON · Pharmaceuticals

Diligence memoA one-page analyst read on Macrotope, Inc. — recommendation, valuation, rhythm, risks.
$900K
Total raised · real
3
Rounds
1.3×
Latest step-up
Top 83%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Macrotope, Inc. looks fair against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.73× the median modeled value of Pre-Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era.
  • Within the normal band (73% of peer median) for its niche.
Active
  • Last raise 13 mo ago; this sector typically re-raises about every 13 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Macrotope, Inc. is one of 1610 Pharmaceuticals companies tracked from PRINCETON. By capital raised it ranks in the long tail (ahead of 18% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2025-05-27
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3M$2.5M$3.8M$5.0MPre-Seed · 2022-05-20 Raised $200K (real) Modeled valuation $3.1M (est)$200K$3.1MPre-Seed2022Pre-Seed · 2023-08-14 Raised $300K (real) Modeled valuation $2.3M (est)$300K$2.3MPre-Seed2023Pre-Seed · 2025-05-27 Raised $400K (real) Modeled valuation $1.1M (est)$400K$1.1MPre-Seed2025+$300K+$400KCumulative $900K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$200K · 2022
Pre-Seed extension$300K · 2023
Pre-Seed extension$400K · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$1.1M
Base estimate est.
$224K
Conservative case
$2.7M
Upside case
$2.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $3.1M · 2022-05-202022Pre-Seed · modeled $2.3M · 2023-08-14Pre-Seed · modeled $1.1M · 2025-05-272025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 46% high
1.80×/yr
Annual markup
2.44×/yr upside case
1.1 yr
Elapsed time used
1.1 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
18 mo
Avg between rounds
$298K/yr
Capital velocity
4.1 yr
On record since
2022
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$900K
Sector median$8.1M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.0× of median
This company$400K
Sector median$421K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$1.1M
Sector median$76.1M

Raised more than 18% of sector peers (real $). Modeled value above 2% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #12 of 19.

This companyCohort peer
$100K$1.0M$10.0M$100K$1.0M$10.0MCapital raised (log)Fedora Pharmaceuticals Inc. · Pre-Seed Raised $1.1M · modeled $2.5M (est)PRG FlowChem, Inc. · Pre-Seed Raised $825K · modeled $2.5M (est)Adora Animal Health Corp · Pre-Seed Raised $1.0M · modeled $2.5M (est)ABLi Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $2.2M (est)NextEvo, Inc. · Pre-Seed Raised $600K · modeled $2.0M (est)Etheros Pharmaceuticals Corp. · Pre-Seed Raised $1.7M · modeled $1.9M (est)Neuro-Innovators LLC · Pre-Seed Raised $640K · modeled $1.8M (est)PridCor Therapeutics, LLC · Pre-Seed Raised $1.0M · modeled $1.8M (est)NOXX Therapeutics, Inc. · Pre-Seed Raised $1.5M · modeled $1.7M (est)Vogenx, Inc. · Pre-Seed Raised $750K · modeled $1.5M (est)Accretion Therapeutics, Inc. · Pre-Seed Raised $750K · modeled $1.3M (est)Macrotope, Inc. (this company) Raised $900K · modeled $1.1M (est)Macrotope, Inc.
CompanyStageRaised · realValue · estvs peer med.
Fedora Pharmaceuticals Inc.Pre-Seed$1.1M$2.5M1.72×
PRG FlowChem, Inc.Pre-Seed$825K$2.5M1.70×
Adora Animal Health CorpPre-Seed$1.0M$2.5M1.69×
ABLi Therapeutics, Inc.Pre-Seed$1.0M$2.2M1.53×
NextEvo, Inc.Pre-Seed$600K$2.0M1.36×
Etheros Pharmaceuticals Corp.Pre-Seed$1.7M$1.9M1.32×
Neuro-Innovators LLCPre-Seed$640K$1.8M1.23×
PridCor Therapeutics, LLCPre-Seed$1.0M$1.8M1.22×
NOXX Therapeutics, Inc.Pre-Seed$1.5M$1.7M1.18×
Vogenx, Inc.Pre-Seed$750K$1.5M1.00×
Accretion Therapeutics, Inc.Pre-Seed$750K$1.3M0.91×
Macrotope, Inc. this companyPre-Seed$900K$1.1M0.73×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$200K2022-05-20$1.1M$3.1M90%
Pre-Seed$300K2023-08-14$1.7M$2.3M90%
Pre-Seed$400K2025-05-27$2.2M$1.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$200K2022-05-20
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Pre-Seed$300K2023-08-14
    • Raised 15 mo later, in step with the ~13 mo sector norm.
    • Round 1.5× larger than the prior — scaling up.
    • 1 investor on this round.
  3. Pre-Seed$400K2025-05-27
    • Raised again after 21 mo — slower than the ~13 mo sector norm.
    • Round 1.3× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2026 ~Q4
Modeled next raise · ~18mo cadence
$533K
Modeled next size est.range $400K$853K
1.3×
Last step-up
$298K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Stephen Anderson3 other2022-05
Elliot Campbell2022-05
Elliot Camptbell2025-05
Registry & provenance

Macrotope, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1913044
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Ionia Pharmacy, LLCPharmaceuticalsPre-Seed$900K$7.1Msame sector · same stage
Ascalon International, Inc.PharmaceuticalsPre-Seed$905K$4.7Msame sector · same stage
Edison Oncology Holding CorpPharmaceuticalsPre-Seed$882K$8.8Msame sector · same stage
Oncoquest Pharma Usa, IncPharmaceuticalsPre-Seed$870K$10.5Msame sector · same stage
Tetra Discovery Partners LlcPharmaceuticalsPre-Seed$945K$13.2Msame sector · same stage
Eleison Pharmaceuticals IncPharmaceuticalsPre-Seed$980K$15.9Msame sector · same stage
PRG FlowChem, Inc.PharmaceuticalsPre-Seed$825K$2.5Msame sector · same stage
7 Hills Pharma Inc.PharmaceuticalsPre-Seed$1.0M$4.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
VasoRx, Inc.PharmaceuticalsSeed$117.9M83%
Avitide, Inc.PharmaceuticalsSeries A$309.7M83%
Shuttle Pharmaceuticals Holdings, Inc.PharmaceuticalsSeries A$7.0M82%
LGM Holdings, LLCPharmaceuticalsSeed$35.2M82%
Oligomerix, Inc.PharmaceuticalsSeed$37.8M82%
Kp Biosciences, Inc.PharmaceuticalsPre-Seed$13.2M82%
Cutispharma Holdings, Inc.PharmaceuticalsSeries C$2.5B81%
Enumeral Biomedical Holdings, Inc.PharmaceuticalsSeries B$22.7M81%
Frequently asked
How much funding has Macrotope, Inc. raised?
Macrotope, Inc. has raised approximately $900K in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Macrotope, Inc.'s estimated valuation?
Provath's modeled valuation for Macrotope, Inc. is approximately $1.1M (modeled range $224K–$2.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Macrotope, Inc. at?
Macrotope, Inc.'s latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Tue May 27.
What does Macrotope, Inc. do and where is it based?
Macrotope, Inc. operates in the Pharmaceuticals sector, based in PRINCETON.
Explore related

See where Macrotope, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Macrotope, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.